Abstract
In the last decade, there been a major advancement in the treatmnet of rheumatoid arthritis (RA) through novel therapeutic agents introduced gradually in the clinical practice. Bariticinib is a JAK1/2 selective inhibitor which has been show to have good efficacy, tolerance, and so fair, even safety in phase II and III trials.
Its introduction in the treatment id a good alternative to well-established drugs, whether conventional or biological ones.